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This journal is ª The Royal Society ofA GFP-tagged nucleoprotein-based aggregation assay
for anti-influenza drug discovery and antibody
development†
Helma Antonyabc and Patrick M. Schaeffer*abc
Influenza is a viral pandemic that affects millions of people worldwide. Seasonal variations due to genetic
shuffling and antigenic drifts in the influenza viruses have necessitated continual updating of therapeutics.
The growing resistance to current influenza drugs has increased demand for new antivirals. The highly
conserved nature of NP, a multi-functional viral protein that is serotypically distinct and abundantly
expressed during infection, has led to its use in developing universal biotherapeutics and vaccines that
could be effective against the virus, irrespective of its strain variations. Compounds causing aggregation
of NP have recently been shown to be potent antivirals but require the development of new high-
throughput assays capable of screening compounds with similar modes of action. Here, we describe the
development of a new bioassay for the Influenza A nucleoprotein (NP). The assay was developed to
quantify ligand-induced aggregation of a GFP-tagged NP and was validated with aggregation-inducing
compounds such as nucleozin and a NP-specific antibody. The new NP–GFP aggregation assay can be
performed with partially purified or mixtures of proteins and is amenable to a high-throughput format.
Using this assay, we demonstrate the potential of a new anti-NP polyclonal antibody that we have
obtained from chicken. This cost-effective high-yield source of anti-NP IgY has potential for large-scale
production and development of therapeutic antibodies. The simplicity, speed and flexibility of this assay
make it an invaluable tool for timely development of effective antivirals that can help to control future
epidemics.Introduction
Despite years of research into inuenza, this long-known,
highly contagious disease continues to take its toll on millions
of people of all ages every year. A substantial proportion of the
affected suffer the life-threatening variant resulting in a typical
mortality of 250 000–500 000 per u season.1,2 Themajor factors
impeding the development of efficient antivirals are: (1) the
growing resistance of current inuenza strains against existing
drugs; and (2) the continued evolution of the inuenza virus.2,3
Both of these generate strains with varying virulence and
transmissibility each season. The key molecular event respon-
sible for this is the genetic reassortment or gene shuffling that
occurs in the course of a viral infection. During viral RNA
replication in a host cell infected with multiple inuenzavelopment of Therapeutics, James Cook
-mail: patrick.schaeffer@jcu.edu.au
harmacy and Molecular Sciences, James
lia
s, James Cook University, Douglas, QLD
tion (ESI) available. See DOI:
Chemistry 2013strains, segments of the viral RNA genome get shuffled
randomly (genome reassortment). The newly assembled viral
progeny may contain mutations that empower the new strains
with properties like drug-resistance or evasion of pre-existing
host immunity (cf. ‘antigenic dri’). For example, the 2009
H1N1 pandemic strain (H1N1pdm09 S-OIV), which is a reas-
sortant progeny of the avian, human, and swine inuenza
viruses,4 was found to be resistant to oseltamivir [Tamiu] in
patients with prior exposure to the drug due to accumulation of
mutations in the drug-binding site.5,6 Therefore, there is a
crucial need to develop antivirals that can surpass the seasonal
variation and drug-resistance issues in order to be efficient.
Current inuenza drugs are comprised of neuraminidase
inhibitors (oseltamivir/Tamiu, zanamivir/Relenza, peramivir
and laninamivir) and adamantine derivatives (amantadine and
rimantadine) that exclusively target the viral envelope and
membrane proteins, neuraminidase (NA) and M2 hydrogen ion
channel, respectively.2,3 Both these proteins are highly prone to
mutations and thus develop drug resistance rapidly.2,3
Furthermore, the only approved prophylactic measure currently
available employs immunotherapy using neutralising anti-
bodies that target the mutation-prone envelope protein hae-
magglutinin (HA).7 As a result of seasonal variation in the HAAnalyst, 2013, 138, 6073–6080 | 6073
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View Article Onlineprotein, these vaccines are continually reformulated and
annually re-administered to the public at a great expense. Even
then, these vaccines do not protect against novel ‘antigenic-
shi’ subtypes that have evolved with changes in the entire HA
gene, and thus posing pandemic risks such as the H3 subtype in
the 1968 pandemic.
NP is a biologically signicant multi-functional protein
critical for viral RNA replication, genome trafficking and viral
assembly.8 More importantly, NP is serotypically distinct8 and
extensively conserved among Inuenza A strains.8–10 The
evolution rate of the inuenza viral genes is estimated to be 2 
106 higher than that of eukaryotic gene equivalents,11 with an
average nucleotide substitution rate of up to 4.6  103
substitutions per site per year in HA genes,12 and up to 4.4 
103 substitutions per site per year in NA genes.13,14 In
comparison, the NP gene has only 2.4  103 substitutions
per site per year according to a recent large-scale analysis of
>5000 NP nucleotide sequences.15 At the protein level, only
30.1% amino acid residues were found to be polymorphic in NP,
out of the 2500 Inuenza A NP sequences analysed.10 Further-
more, NP is abundantly expressed during infection16 and readily
detected as early as 2 days post-infection in mouse models.17
Recently, several groups have investigated the potential of
NP as an antiviral target and have identied a few prospective
drugs – i.e. nucleozin and its analogues – that cause aggregation
of NP, thereby blocking its functions, such as viral genome
trafficking18 and replication.19–22 These compounds were shown
to be effective against a broad range of Inuenza A viral strains
including H1N1, H3N2, and H5N1 in cell culture experiments
and against highly pathogenic avian inuenza (HPAI) H5N1 in
mouse models.19–22 However, in view of the evolution of strain
variants and drug resistance, there is also a need to identify NP
mutants that are likely to be resistant to these drugs.
Owing to its ability to confer heterosubtypic immunity, anti-
NP antibodies have recently received increasing emphasis in
developing a universal vaccine. Thus far, vaccinations with
puried NP or DNA vectors have been the main mode of elic-
iting the antibody response.23–26 The potential of non-neutral-
ising anti-NP antibodies that are elicited by natural infectionFig. 1 Principle of NP–GFP aggregation assay. The ligand-induced aggregation or a
soluble and aggregated or agglutinated fluorescent proteins. The fraction of aggre
fugation and measured by fluorimetry. Ab: antibody.
6074 | Analyst, 2013, 138, 6073–6080and these vaccinations are shown to play an important role in
conferring heterosubtypic immunity.27 Furthermore, passive
administration of anti-NP antibodies to naive mice has not only
been shown to convey protection against infection,27 but also
rescues the reduced heterosubtypic immunity up to 1.5 years
post-infection.28 Nevertheless, it was noted that mice required
an injection of puried anti-NP IgG to a nal serum titer of 105
in order to reduce the viral load.17 Large-scale production of
anti-NP antibodies for passive administration would thus be an
ideal strategy to boost antibody titers.
In birds, the circulating serum antibodies are transferred to
egg yolks as a means of conferring passive immunity to the
embryos.29 Chicken immunoglobulin (IgY) is very similar to
mammalian IgG and highly stable.30–34 IgY has been used
successfully for therapeutic and prophylactic administration in
humans and animals with good tolerance and no complement
activation.35,36 Passive administration of IgY can be accom-
plished via oral or intranasal routes.37,38 In recent years, this
non-invasive technology is being increasingly utilised as a
cheap source of antibody production owing to its high and long-
lasting yields (up to 2 years).39 A typical egg laying hen can yield
1500 mg IgY per month, of which 2–10% is antigen-specic
IgY.40 As IgYs are the only antibody isotype present in the egg
yolk, extraction is fast and simple. Compared to other sources of
antibody production, hyperimmunised chickens oen produce
antibodies against highly conserved epitopes that may not
normally be recognised by mammalian immune systems;37
thereby increasing the chances of obtaining a higher affinity
antibody against the desired antigen. Passive administration of
polyclonal IgY generated against H5N1 and H1N1 viruses has
previously been shown to be efficacious in conferring protection
against homologous and heterologous lethal challenge infec-
tion in mice.37,41 A further study has demonstrated the in vitro
antiviral activity of anti-Inuenza B IgY.42
Here, we report for the rst time the production of a highly
specic polyclonal anti-NP IgY from chicken egg yolks that has
potential for immunotherapy and the development of a simple
and fast aggregation-based in vitro assay (Fig. 1) capable of
identifying NP-targeting biologics and chemicals with a similargglutination of NP–GFP fusion proteins produces a heterogeneous population of
gated or agglutinated NP–GFP and the soluble fraction are separated by centri-
This journal is ª The Royal Society of Chemistry 2013
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View Article Onlinemode of action to that of nucleozin, i.e. specic aggregation of
NP.19–22Materials and methods
Reagents
The H1N1 NP puried from A/Beijing/262/95 H1N1 inuenza
virus infected chicken eggs was obtained from Virusys Corpo-
ration, Taneytown, MD. Nucleozin was obtained from Chem-
Bridge Corporation, San Diego, CA.Cloning
Escherichia coli strain DH12S was used routinely as the host
strain during construction of vectors. The NP used in this
study was originally derived from pGEM-NP containing the
NP sequence of A/Viet Nam/1203/2004 (H5N1) (Gen-
Bank:AAW80720).43 To generate pET–His6–NP (pHA228), the
pET–His6–NP–GFP43 was digested with NheI, end-lled and
re-ligated to introduce a stop codon at the end of the NP open
reading frame, thereby eliminating the C-terminal GFP coding
sequence. The vector pET16bD2 encoding the domain III of the
Dengue (DENV-2 TSV01) virus envelope protein (EDIII) with an
N-terminal 6-His-tag44,45 was a kind gi from A/Prof. Subhash
Vasudevan (Duke-NUS, Singapore).Protein expression and purication
Vectors were transformed into the E. coli strain BL21(DE3)RIPL
(Stratagene) for protein expression. NP–GFP43 and NP were
expressed and puried using Pronity IMAC Ni-charged resin
(Bio-Rad) as described previously.46 Briey, cultures were grown
at 37 C in OvernightExpress Instant TB Medium (Novagen)
until an OD600 of 0.5 was reached, followed by incubation at
16 C with vigorous shaking for 3 days. Harvested cells were
resuspended in lysis buffer 1 (45 mM Na2HPO4, 5 mM NaH2PO4
(pH 7.8), 300 mM NaCl, 10% (v/v) glycerol, 2 mM b-mercap-
toethanol, 10 mM imidazole), lysed at 10 000 psi using a French
pressure cell and centrifuged at 40 000g for 30 min at 4 C.
Eluted fractions containing NP and NP–GFP in elution buffer
1 (lysis buffer 1 + 200 mM imidazole) were precipitated at 4 C
with 0.3 and 0.5 g ml1 (NH4)2SO4, respectively and centrifuged
at 18 000g for 30min at 4 C. GFP,46NP and NP–GFP pellets were
resuspended and stored in buffer A (45 mM Na2HPO4, 5 mM
NaH2PO4 (pH 7.8), 300 mM NaCl, 10% (v/v) glycerol) and buffer
B (45 mMNa2HPO4, 5 mMNaH2PO4 (pH 7.8), 10% (v/v) glycerol,
2 mM b-mercaptoethanol), respectively. GFP was stored in
buffer B. For aggregation studies with nucleozin, the NP–GFP,
GFP and NP proteins were dialysed with buffer C (50 mM Tris–
Cl (pH 7.5), 100 mM NaCl) consistent with previous studies.19,47
For the control viral protein EDIII: following transformation
with pET16bD2, E. coli BL21(DE3)RIPL cells were grown at 16 C
with vigorous shaking (200 rpm) in OvernightExpress Instant
TB Medium (Novagen) for 4 days. Cells were lysed and centri-
fuged as above. The pellet containing EDIII was refolded from
inclusion bodies using a modication of a previously described
protocol.44 Briey, the pellet was washed in 1 M urea and 2%
Triton X-100, centrifuged at 40 000g for 30 min at 4 C, andThis journal is ª The Royal Society of Chemistry 2013solubilised in lysis buffer 2 (18 mM Na2HPO4, 2 mM NaH2PO4
(pH 7.8), 300 mM NaCl, 8 M urea, 10 mM b-mercaptoethanol,
nal pH 8.25) overnight. The soluble fraction was loaded onto a
Pronity IMAC Ni-charged resin (Bio-Rad) pre-equilibrated with
the same buffer. Proteins were eluted with elution buffer 2 (lysis
buffer 2 + 200 mM imidazole) and refolded by dialysis (10 000
MWCO SnakeSkin pleated dialysis tubing, regenerated-cellu-
lose, Pierce) against MilliQ water (1 l  2) for 28 h at 4 C.
All puried proteins were assessed for purity by SDS-PAGE
and quantied by standard Bradford assay (Sigma).Production and purication of IgY
Female leghorn chickens Gallus gallus were repeatedly immu-
nised (i.e. 6 boosters following primary) via intramuscular
injections of 100 mg puried NP mixed 1 : 1 (v/v) with adjuvant
(Emulsigen, Intervet). As a negative control, another set of
chickens was repeatedly immunised with puried EDIII mixed
with adjuvant. Eggs were collected 3–4 weeks post-immunisa-
tion and the IgY was extracted and puried from the yolks using
modied PEG precipitation and dialysis.48 Briey, the yolk was
separated from the egg whites and the IgYs in the yolk were
puried by a 2-step precipitation with PEG 6000 at a nal
concentration of 12% (w/v). Following precipitation, the IgY
extract was dialysed in PBS. IgYs were assessed for purity by
SDS-PAGE (reducing and non-reducing) and quantied by
standard Bradford assay (Sigma).Immunoblotting
Samples of puried recombinant proteins separated by SDS-
PAGE were transferred onto PVDF membrane (BioRad) pre-wet
with methanol for 30 s, via semi-dry electroblotting at 15 V for
25 min in transfer buffer (0.19 M glycine, 25 mM Tris).
Following blocking with 5% skim milk in PBS buffer (10 mM
Na2HPO4, 1.5 mM NaH2PO4 (pH 7.4), 137 mM NaCl, 2.7 mM
KCl) at RT for 1 h, blots were probed with diluted (1 : 1000 in 1%
skimmilk in PBS buffer) anti-NP or anti-EDIII IgYs at RT for 1 h.
Aer washing three times for 5 min with PBS-T buffer (PBS +
0.05% (v/v) Tween-20), blots were probed with peroxidase-
conjugated anti-IgY (Jackson Immunoresearch Laboratories
Inc.) diluted 1 : 5000 in 1% skim milk in PBS buffer for 1 h at
RT. PVDF membranes were washed again three times with PBS-
T buffer and developed with 5 ml SIGMAFAST 3,30-dia-
minobenzidine/H2O2 solution to visualise immunoreactive
bands.NP–GFP aggregation assay with nucleozin
For the aggregation reactions, 9 volumes of NP, NP–GFP and
GFP proteins in buffer C, were treated individually or as
mixtures, with 1 volume of increasing concentrations of
nucleozin in DMSO and incubated at room temperature (RT,
25 C) for 1 h. Reactions were performed in a total reaction
volume of 75 ml and at a nal concentration of 4 mM NP. Aer
incubation, reactions were centrifuged at 15 000g for 30 min at
4 C in a bench-top centrifuge (Eppendorf 5810R, rotor: F45-48-
PCR). Quantication was carried out using densitometricAnalyst, 2013, 138, 6073–6080 | 6075
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View Article Onlineanalysis and/or by measuring the uorescence in the superna-
tant as previously described.43,49
Briey, for densitometric analysis, 10 ml of supernatant was
subjected to SDS-PAGE followed by Coomassie blue staining.
Protein bands were integrated using ImageJ soware (http://
rsbwed.nih.gov/ij/) and normalised against bands obtained for
control (untreated) reactions as previously described.49 For
uorescence measurements, 50 ml supernatants were trans-
ferred to a black 96-well plate (Nunclon) and read in a uores-
cence plate reader (Victor V Wallace Perkin-Elmer) with 40 nm
band-width lters at excitation and emission settings of 355 nm
and 535 nm, respectively.
Soluble fractions (Fsol) were calculated by dividing the uo-
rescence value obtained for a reaction (+nucleozin) with the
uorescence value of a control reaction (nucleozin).NP–GFP agglutination assay with IgY
NP–GFP was mixed 1 : 1 (v/v) with varying concentrations of IgY
(in PBS) in 30–90 ml reaction volumes and incubated at RT for 30
min. The nal concentration of NP–GFP was 0.5 mM in the
reaction volume, except for the concentration-dependent
agglutination where varying concentrations of NP–GFP were
used as specied (Fig. 3E). Aer incubation, reactions were
centrifuged at 15 000g for 30 min at 4 C. The pellets were
analysed by SDS-PAGE and silver staining.50 Densitometric
quantication of the stained protein bands and the uores-
cence in the supernatants were determined as above.Fig. 2 Quantitative determination of nucleozin-induced NP aggregation. (A)
SDS-PAGE of the supernatants of a NP, NP–GFP and GFP protein mixture treated
with increasing concentrations (2, 4, 20, 40 mM) of nucleozin at RT for 1 h (top
panel) and the corresponding electropherogram generated by ImageJ analysis
(bottom panel). CP is an unidentified protein that co-purified with NP. (B)
Aggregation curves obtained by densitometric analysis of NP, NP–GFP and GFP
protein mixture treated with increasing concentrations of nucleozin at RT for 1 h
(n ¼ 3, see Table S1 in ESI†). (C) SDS-PAGE of the supernatants of NP and NP–GFP
separately treated with increasing concentrations (2, 4, 20, 40 mM) of nucleozin at
RT for 1 h. (D) Aggregation curves obtained by densitometric analysis of sepa-
rately treated NP (closed circles) and NP–GFP (closed squares) with increasing
concentrations of nucleozin at RT for 1 h. The fluorescent supernatants of NP–GFP
(open squares) were also quantified by fluorimetry (n ¼ 3, see Table S2 in ESI†).Results
Principle of NP–GFP aggregation assay
We have previously developed an assay called GFP-Basta to
measure the ligand-induced thermal stabilization of a protein
of interest.49 We applied this assay on NP–GFP and identied an
NP-binding ssDNA that was further applied to develop an
ultrasensitive immuno-PCR assay.43 A further assay based on
differential scanning uorimetry of GFP-tagged proteins51 was
recently applied to NP–GFP, but the intrinsic high stability of
NP was a limiting factor for this assay and could therefore not
be applied for high-throughput screening of stabilizing
compounds. Building on these previous observations and
limitations, a new NP–GFP aggregation assay was developed to
allow identication of NP-targeting anti-inuenza agents with
similar modes of action to that of nucleozin, i.e. irreversible and
specic aggregation of NP.19–22 The NP–GFP aggregation assay
uses GFP tethered to the C-terminus of NP as a quantitative
reporter of NP aggregation and is applied for the detection of
chemically-triggered NP aggregation at room temperature
(Fig. 1). Following treatment of NP–GFP with molecules trig-
gering aggregation of NP in a 96-well PCR plate, the reaction is
centrifuged and the soluble fraction (Fsol) of NP can be directly
determined from the fraction of residual uorescence corre-
sponding to the fraction of soluble NP–GFP in the supernatant.
The quantication can be performed by uorimetric analysis
using a uorescence plate reader or by SDS-PAGE and densito-
metric analysis of protein bands.6076 | Analyst, 2013, 138, 6073–6080Validation of NP–GFP aggregation assay with nucleozin
Nucleozin inhibits NP functionality by aggregating NP mole-
cules into high-order oligomers.19,21 To validate the utility of
NP–GFP for developing an aggregation-based drug screening
assay, we tested and compared the effect of nucleozin on NP–
GFP, GFP and NP. Nucleozin and protein samples were mixed
and incubated at room temperature for 1 hour. Thereaer, the
protein aggregates were removed by centrifugation and the
soluble fractions of each protein was quantitated by SDS-PAGE
and densitometry (Fig. 2A). In order to eliminate the effect of
buffer variation and allow direct comparison of specic drug-
induced effects on the different proteins in identical conditions,
we rst treated a mixture of GFP (4 mM), NP (2 mM) and NP–GFP
(2 mM) with increasing concentrations of nucleozin (2, 4, 20 and
40 mM) for 1 h. Comparison of the aggregation curve of NP with
that of NP–GFP immediately suggested that nucleozin aggre-
gates NP slightly more efficiently than NP–GFP (Fig. 2B).
Nevertheless, the data also demonstrated that a similar
concentration-dependent aggregation was triggered by nucleo-
zin in both NP and NP–GFP, while GFP remained unaffected
across all nucleozin concentrations (Fig. 2B). An unidentied
protein (CP) that co-puried with NP was also observed to beThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlineunaffected by nucleozin and hence was used as a control in the
densitometric method (Fig. 2A). A second experiment was per-
formed where NP (4 mM) and NP–GFP (4 mM) were analysed
separately in the presence of increasing nucleozin concentra-
tions under similar conditions (Fig. 2C). Here again, we
observed that the aggregation of NP–GFP is slightly inhibited
compared to NP (cf. Fig. 2B and D). Yet NP–GFP was consistently
aggregated by nucleozin and can therefore be applied as a
reporter for NP aggregation. The Fsol of NP–GFP for each
nucleozin concentration was quantied by uorimetry and
reected the densitometric data (Fig. 2D). A slightly higher
background was observed with the uorimetric method but
saturation curves were otherwise identical. The data suggests
that the aggregation of NP in the fusion protein is slightly
inhibited by the presence of GFP, probably through either a
kinetic and/or steric effect. The absence of any ligand-induced
effect on GFP or control indicated the specicity and sensitivity
of the assay with partially puried or mixtures of proteins.
Together, these results validate the use of NP–GFP aggregation
based assay for drug screening and resistance proling studies.
Finally, a kinetic evaluation of the assay demonstrated that 1 h
incubation with nucleozin was optimal for uorimetric quan-
titation of aggregation and assay reproducibility but that longer
incubation times could be used if needed (Fig. S1, ESI†).Validation of NP–GFP aggregation assay with anti-NP chicken
antibody
In a next step, we investigated the potential of the NP–GFP
aggregation assay to be applied for the screening of biologics
promoting aggregation of NP, such as NP-specic antibodies.
Recombinant NP expressed in E. coli has previously been shown
to efficiently elicit cross-protective immunity inmice.52Here, NP
was expressed in E. coli and puried by Ni-affinity chromatog-
raphy. The puried proteins were then used to immunise
chickens. The anti-NP chicken IgYs were puried from the egg
yolks of immunised chickens (Fig. 3A) and analysed by immu-
noblotting (Fig. 3B). The anti-NP IgY fraction obtained showed a
strong and specic reactivity against our recombinant H5N1 NP
as well as a viral H1N1 NP. Additionally, the Dengue virus
envelope protein (EDIII) was produced to serve as a negative
control and for the production of a non-specic IgY fraction that
was used as a negative control. No reactivity was observed with
the negative control (EDIII, 15 kDa). The negative control anti-
EDIII IgY showed no reactivity against our recombinant H5N1
NP.
Next, we investigated the effect of increasing concentrations
(0.625–30 mM) of IgY on NP–GFP (0.5 mM). Aer 30 min incu-
bation at room temperature, the extent of NP–GFP agglutina-
tion was determined aer centrifugation and SDS-PAGE.
Agglutination of NP–GFP was observed at concentrations
starting from 5 mM anti-NP IgY, while no agglutination was
caused by anti-EDIII IgY at any tested concentration (Fig. 3C).
Qualitative assessment of the protein pellets aer centrifuga-
tion and UV transillumination conrmed these ndings (data
not shown). The faint bands observed in the absence of IgY
represent background levels of NP–GFP aggregation (Fig. 3C).This journal is ª The Royal Society of Chemistry 2013Fluorimetric quantitation of the reaction supernatants further
conrmed these observations (Fig. 3D).
Antibody-mediated agglutination is dependent on both the
concentrations of antibody and antigen, i.e. NP–GFP. We
investigated the effect of increasing concentrations of NP–GFP
against a dilution series of IgY to demonstrate that antibody-
mediated agglutination was indeed responsible for aggregation
of NP–GFP (Fig. 3E). As expected, when higher concentrations of
NP–GFP were used a proportionally higher concentration of NP-
specic IgY was needed to induce NP–GFP agglutination.
Together, these results validate the use of the NP–GFP aggre-
gation assay for the quantitative detection of NP-specic
antibodies.Discussion
Nucleozin and its analogues are a new class of promising
inuenza antivirals. They show potent antiviral activity in cell
culture and mouse model experiments due to their ability to
aggregate NP. In spite of the conserved nature of NP, some of
these aggregating compounds were inactive against NP variants
harbouring particular mutations.19–22 The simplicity and speed
of our NP–GFP aggregation assay offers the much needed
technology to fast-track the screening and development of new
compounds with similar modes of action. Our NP–GFP aggre-
gation assay is an attractive alternative to the recently developed
uorescence quenching assay47 as it can be applied with
partially puried proteins, eliminating the need for elaborate
protein purication. The GFP domain was not subject to
aggregation which demonstrates that nucleozin is very specic.
GFP can therefore be used as a control protein, i.e. if GFP
aggregation is induced by a compound it would be classied as
non-specic. The variant of GFP (GFPuv) used in this study is
thermostable in a pH range between 5 and 12.53 This broad pH
range can be useful to study the effect of pH on ligand-induced
aggregation of NP.
We anticipate that the assay could be translated into a high-
throughput format through the replacement of the centrifuga-
tion step by a ltration step and the use of appropriate liquid
handling robotics. Moreover, both induction and inhibition of
protein aggregation can be monitored using this assay. Further
applications of this assay format could therefore be extended to
study aggregation-prone proteins such as prions, Alzheimer's
Ab and tau. Limiting protein aggregation is a key issue
encountered across all stages of the biopharmaceutical formu-
lation and drug development process. This assay could be
applied to monitor buffer-induced and undesirable protein
aggregation.
The newly developed anti-NP IgY demonstrated specic
affinities against both recombinant H5N1 and viral H1N1 NP.
This cost-effective, high-yield source of anti-NP IgY has poten-
tial for large-scale production and development of therapeutic
antibodies. The NP–GFP agglutination induced by the new anti-
NP IgY was concentration-dependent and demonstrated that
the assay could be applied to its quantitation. Hence, it could
also be used as a simple screening assay across multiple hosts
(i.e. humans, birds, pigs) and multiple inuenza subtypes.Analyst, 2013, 138, 6073–6080 | 6077
Fig. 3 IgY-induced NP–GFP agglutination. (A) SDS-PAGE of IgY purified from a chicken immunized with NP. (B) Immunoreactivity of anti-NP IgY probed against 3.4 mg
of NP and 5.6 mg EDIII (left panel). Immunoreactivity against 4 ng each of viral H1N1 NP and recombinant H5N1 NP (right panel). (C) NP–GFP agglutination with
increasing concentrations (0.625, 1.25, 2.5, 5, 10, 20, 30 mM) of anti-NP IgY (top panel) and of anti-EDIII IgY (bottom panel). Input: initial amount NP–GFP added to each
reaction. Protein bands are revealed by silver staining after SDS-PAGE under non-reducing conditions. Representative gel (n ¼ 3). (D) Residual NP–GFP fluorescence in
the reaction supernatants after agglutination with increasing concentrations (3, 6, 10, 13 mM) of anti-NP or of anti-EDIII (negative control) IgY (n¼ 2). (E) Concentration-
dependent NP–GFP agglutination with increasing concentrations of NP–GFP and anti-NP IgY. Residual fluorescence was measured in the reaction supernatants and
expressed in soluble fractions (Fsol) (n ¼ 2).
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View Article OnlineCurrent methods for epidemiological surveillance of inuenza
in avian species rely on serological and egg yolk testing via virus
isolation, reverse transcriptase-PCR, blocking enzyme-linked
immunosorbent assay, agar gel immunodiffusion test and latex
agglutination tests.54–56 Comparatively, the NP–GFP agglutina-
tion assay offers a fast, simple and low-cost screening alterna-
tive for both serum (data not shown) and egg-derived IgY.
Screening egg yolks has been found to be a more cost-effective
method for poultry surveillance57 and our data demonstrate the
capability of our assay for testing puried IgY from egg yolk.
Furthermore, recent strategies of vaccine development are
based on eliciting NP antibodies. In a recent phase I clinical
trial, modied vaccinia virus Ankara (MVA) vector expressing
inuenza NP andmatrix protein 1 (MVA-NP + M1) elicited a safe
and immunogenic response in humans.58 Here, the NP–GFP
assay could be used to measure antibody titre post-vaccination
and evaluate vaccine efficacies.
In conclusion, the NP–GFP assay is simple, rapid and
versatile as it can be applied to the screening of drugs and
antibodies targeting NP. The ligand-induced aggregation of NP
can be accurately measured irrespective of its binding site. The
assay requires minimal protein purication and offers sensitive
quantitation even in protein mixtures, which is an advantage
when monitoring the effect of biologics such as antibodies.
Finally, with its exibility, we believe that NP–GFP aggregation6078 | Analyst, 2013, 138, 6073–6080assay will be a versatile tool for both inuenza research and the
development of new NP-targeting antivirals.Acknowledgements
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